Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Naoto, Noda"'
Autor:
Naoto Noda, Takeshi Takagaki, Yasuhide Yodo, Yuzo Horibuchi, Shuichi Iino, Shunji Matsuki, Yoichiro Ogama, Hiroyoshi Kakuyama
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract This study examined the safety, tolerability, and pharmacokinetics (PK) of napabucasin in healthy Asian and non‐Asian participants and investigated the potential for QT/QTc interval prolongation. This five‐part (A–E) study proceeded in
Externí odkaz:
https://doaj.org/article/b804592a5ce74d749d7cb7315b7cacf7
Autor:
Takeshi Takagaki, Hirotaka Kawai, Yasushi Fujio, Tatsuto Hamatani, Yoshikazu Kaji, Naoto Noda, Hiroyoshi Kakuyama, Yasuhide Yodo
Publikováno v:
Clinical Pharmacology in Drug Development. 9:938-951
Minesapride (drug code: DSP-6952) is a potential gastrointestinal prokinetic agent with high selectivity for 5-hydroxytryptamine 4 (5-HT4 ) receptor that acts as a partial agonist. Although 5-HT4 receptor agonists are expected to show efficacy in pat
Autor:
Naoto Noda, Tatsuto Hamatani, Yuta Shibue, Takeshi Takagaki, Atsushi Kitamura, Miwa Haranaka, Yoichiro Ogama, Hiroyoshi Kakuyama
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(10)
EPI-589 attenuates oxidative stress due to the radical scavenging activity of the reduced form and affects mitochondrial energy metabolism as a substrate of quinone-oxidoreductases. Given the effects of EPI-589 on oxidative stress and mitochondrial d
Autor:
Takeshi Takagaki, Yasuhide Yodo, Naoto Noda, Yoichiro Ogama, Yuzo Horibuchi, Shunji Matsuki, Hiroyoshi Kakuyama, Shuichi Iino
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives
This study examined the safety, tolerability, and pharmacokinetics (PK) of napabucasin in healthy Asian and non‐Asian participants and investigated the potential for QT/QTc interval prolongation. This five‐part (A–E) study proceeded in a stepwi
Autor:
Naoko Maeda, Saori Sugimoto, Momoko Nishikori, Kimikazu Matsumoto, Takashi Ikeda, Hideo Kitagawa, Hiroaki Goto, Naoto Noda, Eisei Kondo, Junichi Hara
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Thiotepa is used in high-dose chemotherapy (HDT) before autologous hematopoietic stem cell transplantation (HSCT) to treat solid tumors and hematological malignancies. This Phase 1 study was conducted to establish the pharmacokinetics (PK) of
Autor:
Tatsuto, Hamatani, Naoto, Noda, Takeshi, Takagaki, Yasuhide, Yodo, Hirotaka, Kawai, Hiroyoshi, Kakuyama, Yoshikazu, Kaji, Yasushi, Fujio
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(8)
Minesapride (drug code: DSP-6952) is a potential gastrointestinal prokinetic agent with high selectivity for 5-hydroxytryptamine 4 (5-HT
Publikováno v:
Journal of Clinical Oncology. 39:477-477
477 Background: Napabucasin is an orally-administered NAD(P)H quinone dehydrogenase 1–bioactivatable investigational agent hypothesized to affect multiple oncogenic cellular pathways including STAT3. Methods: Food effects on napabucasin pharmacokin
Publikováno v:
Journal of Materials Science. 52:2825-2835
In situ formation of highly dispersed 2–5 nm Ru nanoparticles was successfully achieved in highly Ru-doped (40% Ru) perovskite cathode material, Ru-doped La0.3Sr0.6TiO3 (LSTR), used for electrochemical ammonia synthesis in a proton-conducting fuel
Publikováno v:
ECS Transactions. 68:2663-2670
The electrochemical synthesis of ammonia using solid electrolyte fuel cells with proton conducting solid electrolyte, yttrium-doped barium cerate, was investigated at intermediate temperature (around 500°C). Ru-based electrode catalysts consisting o
Autor:
Tohru AKASHIBA, Yasuo OKADA, Masutaka MIZUTANI, Kazuhiko HIROYASU, Naoto NODA, Akira YAMAGUCHI
Publikováno v:
Japanese Journal of Oral and Maxillofacial Surgery. 61:417-420